COMMERCIALIZATION AND LOGISTICS
Mitigating Risk In Process Automation
Two Chief Technical Officer's for therapeutic organizations cover the various ways in which automation helps to reduce risk and why closing systems and reducing the number of manual manipulations is so critical.
Process Liquids And Buffers Offering
Whether you are a researcher, scientist, or industry professional, this video will provide valuable insights into our large volume liquids manufacturing capabilities.
Supply Chain And Operational Challenges Facing mRNA
Explore some of the biggest supply chain challenges facing mRNA cancer therapeutics and what short-term solutions may exist, starting with Chain of Custody/Chain of Identity.
mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A
During our Cell & Gene Live, mRNA For Cancer Immunotherapy 2024 Outlook, our expert panelists answered audience questions regarding patient safety, foreseeable challenges in mRNA cancer immunotherapy for solid tumors, and much more.
Upstream To Downstream: A Comprehensive Approach To AAV Production
How can you face the challenges of AAV production, scale up your AAV manufacturing effectively, and enhance the recovery and purity in your downstream processing.
Improvements In Scaling And Sequencing For Allogeneic Cell Therapies For Oncology
During this segment, Nguyen and Wagner agree that scalability will be a top concern for most CGT companies.
Driving Down COGS Audience Q&A
Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.
The Way Forward: Supply Chain Solutions
Learn how to build a resilient supply chain to navigate today's complex environment. Expert speakers share insights on optimization, innovation, and strategic planning to meet evolving market conditions.
Manufacturing Hurdles With Viral Vectors
With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and s...
Pipeline Progress
Experts working on robust pipelines that focus on various therapeutic areas explain how process automation looks different per therapeutic focus area.
Thermo Fisher Scientific Bio-Expo Live 2024: Downstream Bioprocessing
Review downstream process tools from Thermo Fisher Scientific to enable optimal biologics purification, including chromatography resins, chemicals, process liquids, and buffers.
Optimize Cell Isolation And Activation For Flexibility And Scalability
Learn about a first-of-its-kind platform technology that enables isolation and activation of T cells in one step using an active release mechanism for clinical trial or commercial manufacturing.
Safety And Efficiency Of Source Material Collection
Expert CTO's detail how automation improves safety and efficiency when collecting source material.
Overcoming Capacity Constraints
How can CGT biotechs overcome issues such as building an in house facility and ultimately get their therapies to patients.
Defining The CMC / Clinical Relationship For Allogeneic Cell Therapies
During this segment, Nguyen and Wagner define why the relationship between CMC and Clinical is so critical, and they also explain what a mutually beneficial partnership between CMC and Clinical looks like.
Auto, Allo, And AI
CTO experts debate autologous and allogeneic, and how automation improves the CAR-T cell process every step from collection to infusion. They also discuss the major ways AI optimizes automation.
Scaling Viral Vectors
Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.
Market Demand For AAV Vectors
Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.
Collaborating with the FDA: Dr. Peter Marks and Dr. Nicole Verdun Share Advice For Small And Emerging Biotechs
In this segment, Dr. Peter Marks and Dr. Nicole Verdun share their advice and best practices for small and emerging biotechs when working with the FDA.
Breaking Down Automated Manufacturing
Experts explain the general benefits of automated manufacturing as well as the key areas that need improvement to scale up quality and to help reduce the costs of therapeutics.
Regulatory Compliance And Viral Vectors
Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.
Quality Control Assays
Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.
Quality Roundtable: Optimizing Biologics Manufacturing Processes With Raw Materials
Improve your commercial manufacturing process with advice from regulatory and raw materials experts on the development journey from pre-clinical to licensure.
Planning for Success: Supply Resiliency Strategies for Bench to Production
Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.
Quality Roundtable: Raw Material Planning For Tech Transfer And Scaling Biologics
Join this roundtable of biopharmaceutical professionals as they share their insights to help you navigate important quality and planning decisions for the progression of your biologic.
An Active Release Mechanism For Magnetic Separation And Cell Isolation
Discover an innovative active release solution that will serve autologous and allogeneic processes to the benefit of cell therapy patients.
Technology Needs For Automated Manufacturing
Investigate the importance of technology as it relates to automation and standardization within cell therapy manufacturing. The panelists in this discussion cover solutions and services needed for process automation in CGT.
How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks
In this segment of Cell & Gene Live, Dr. Peter Marks shared what he and his team have learned from current gene therapy approvals to accelerate future approvals.